300 related articles for article (PubMed ID: 20338710)
21. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates.
Tan TY; Ng LS; Tan E; Huang G
J Antimicrob Chemother; 2007 Aug; 60(2):421-3. PubMed ID: 17540671
[TBL] [Abstract][Full Text] [Related]
22. Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates.
Choi MJ; Park YK; Peck KR; Ko KS
Int J Antimicrob Agents; 2014 Nov; 44(5):475-6. PubMed ID: 25443890
[No Abstract] [Full Text] [Related]
23. Investigation of metallo-beta-lactamase producing strains of Pseudomonas aeruginosa and Acinetobacter baumannii by E-test, disk synergy and PCR.
Aktaş Z; Kayacan CB
Scand J Infect Dis; 2008; 40(4):320-5. PubMed ID: 17934980
[TBL] [Abstract][Full Text] [Related]
24. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
25. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
Kwa AL; Loh C; Low JG; Kurup A; Tam VH
Clin Infect Dis; 2005 Sep; 41(5):754-7. PubMed ID: 16080101
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
[TBL] [Abstract][Full Text] [Related]
27. Emergence of plasmid-mediated quinolone resistance genes in clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa in Henan, China.
Jiang X; Yu T; Jiang X; Zhang W; Zhang L; Ma J
Diagn Microbiol Infect Dis; 2014 Jul; 79(3):381-3. PubMed ID: 24805186
[TBL] [Abstract][Full Text] [Related]
28. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.
Falagas ME; Rafailidis PI; Matthaiou DK; Virtzili S; Nikita D; Michalopoulos A
Int J Antimicrob Agents; 2008 Nov; 32(5):450-4. PubMed ID: 18768302
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Castanheira M; Jones RN; Livermore DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii.
Kempf M; Djouhri-Bouktab L; Brunel JM; Raoult D; Rolain JM
Int J Antimicrob Agents; 2012 Feb; 39(2):180-1. PubMed ID: 22100281
[No Abstract] [Full Text] [Related]
31. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
[TBL] [Abstract][Full Text] [Related]
32. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
Clock SA; Tabibi S; Alba L; Kubin CJ; Whittier S; Saiman L
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):343-6. PubMed ID: 23601454
[TBL] [Abstract][Full Text] [Related]
34. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates.
Vila-Farrés X; Callarisa AE; Gu X; Savage PB; Giralt E; Vila J
Int J Antimicrob Agents; 2015 Nov; 46(5):568-71. PubMed ID: 26395218
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and characterization of class I integrons among Pseudomonas aeruginosa and Acinetobacter baumannii isolates from patients in Nanjing, China.
Gu B; Tong M; Zhao W; Liu G; Ning M; Pan S; Zhao W
J Clin Microbiol; 2007 Jan; 45(1):241-3. PubMed ID: 17122024
[TBL] [Abstract][Full Text] [Related]
36. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates.
Kiratisin P; Apisarnthanarak A; Kaewdaeng S
Int J Antimicrob Agents; 2010 Sep; 36(3):243-6. PubMed ID: 20541913
[TBL] [Abstract][Full Text] [Related]
37. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.
Rice LB
Clin Infect Dis; 2006 Sep; 43 Suppl 2():S100-5. PubMed ID: 16894511
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
[TBL] [Abstract][Full Text] [Related]
39. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):228-32. PubMed ID: 19150711
[TBL] [Abstract][Full Text] [Related]
40. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.
Vidaillac C; Benichou L; Duval RE
Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
